AI is now central to pharmaceutical innovation. From drug discovery to clinical development. Yet many organisations continue to struggle to hire the specialists required to turn AI strategy into operational capability.
Based on our experience supporting AI and data hires across European life sciences companies, this article explores why AI hiring remains one of the most persistent talent challenges in pharma, and what the organisations that succeed do differently.
Pharmaceutical companies have rarely lacked ambition when it comes to artificial intelligence. Investment in AI partnerships, data platforms, and computational research has grown substantially over the past few years.
Yet for many organisations, the gap between strategic ambition and operational delivery remains stubbornly wide, and the single most consistent bottleneck is talent.
This is not primarily a question of candidate supply. AI and machine learning professionals capable of delivering results are in significant numbers globally. The more persistent problem is that pharmaceutical organisations frequently encounter structural, cultural, and organisational barriers that make them less competitive than they could be in a demanding talent market.
Based on our experience supporting AI and data hires across European life sciences companies, the following analysis outlines the key reasons why AI hiring remains one of the hardest challenges in pharma - and what the most successful organisations do differently.
The first challenge is simply the competitive landscape. Pharmaceutical companies are recruiting from the same global talent pool as technology firms, fintech companies, quantitative hedge funds, and a growing number of AI-native biotech startups.
For many machine learning engineers and data scientists, these industries represent the default career path. Tech companies typically offer:
• Faster product development cycles and shorter feedback loops
• Larger, well-resourced engineering teams
• Clear technical career progression
• Mature data infrastructure and compute environments
Compensation at senior levels is rarely the decisive factor - most pharmaceutical companies can compete there. The more common issue is that candidates assess roles based on the technical environment and the credibility of the AI strategy. When organisations cannot articulate how AI connects to scientific outcomes or product development, candidates often choose employers whose roadmaps are more clearly defined.
One of the most structurally difficult challenges in pharma AI hiring is the intersection of machine learning expertise and life sciences knowledge. Most AI professionals enter the field from backgrounds in computer science, mathematics, engineering, or physics. Their exposure to drug discovery pipelines, clinical trial design, regulatory frameworks, or biological data interpretation is typically limited.
At the same time, pharmaceutical organisations frequently prefer candidates who already understand the scientific context in which their models will operate, creating a circular hiring problem that can significantly slow pipelines. Research from Deloitte identifies the shortage of professionals combining AI expertise with life sciences domain knowledge as a primary barrier to AI adoption across biopharma.
In practice, the most effective teams resolve this tension not through a single hire, but through deliberate team composition - pairing machine learning specialists with computational biologists, bioinformaticians, and translational scientists. The organisations that struggle longest are those still searching for one individual to bridge both worlds.
Closely linked to the domain knowledge problem is a pattern we observe frequently: job descriptions that attempt to combine multiple distinct specialisms into a single role. Hiring managers often look for candidates who simultaneously possess:
• Advanced machine learning and deep learning expertise
• Production-level software engineering capability
• Deep familiarity with biomedical or clinical data
• Regulatory awareness
• PhD-level scientific research experience
These profiles exist, but they are exceptionally rare - and searching for them can extend hiring cycles by months. The more productive framing is to recognise that AI roles in pharma tend to fall into distinct, complementary categories:
| Role | Primary Focus |
|
Machine Learning Engineer |
Building production AI systems |
|
Data Scientist |
Modelling and data analysis |
|
Computational Biologist |
Applying modelling to biological systems |
|
Bioinformatician |
Genomics and biological data pipelines |
Organisations that fill roles quickly tend to identify their primary capability gap first, hire to address it, and build complementary expertise across the broader team over time.
Experienced AI professionals do not evaluate roles in isolation. Before accepting an offer, they typically want to understand the broader technical context in which they will be working. Common questions include:
• What specific problems will AI be used to solve - and how clearly are they defined?
• What data is available, and how accessible is it?
• How mature is the organisation’s data infrastructure?
• Will the work have a measurable impact on research or clinical decisions?
In some pharmaceutical organisations, AI initiatives remain exploratory. Teams may sit within IT functions or operate as service units rather than being embedded in scientific programmes. For candidates assessing career opportunities, this creates genuine uncertainty about whether their work will carry strategic weight.
Companies that attract strong AI talent tend to communicate a coherent, credible roadmap - one that positions AI as central to R&D strategy rather than as a parallel technical initiative still searching for its mandate.
Pharmaceutical companies hold some of the most scientifically valuable data in existence: clinical trial results, molecular screening libraries, genomics datasets, and real-world evidence. The challenge is that this data is frequently distributed across legacy systems, siloed within therapeutic areas, or subject to governance constraints that limit accessibility.
Common infrastructure barriers include inconsistent data formats across platforms, limited integration among research systems, time-consuming data preparation requirements, and restricted access due to regulatory or IP considerations. Bain & Company research identifies data accessibility and infrastructure maturity as major barriers to scaling AI across pharmaceutical R&D.
For AI candidates, this is a practical concern as much as a cultural one. Professionals accustomed to working in data-rich, well-integrated environments will conduct their own assessment of data readiness during the interview process. Organisations with fragmented infrastructure often lose candidates at this stage - not because of compensation, but because the environment does not support the kind of work they want to do.
A less frequently discussed but equally important factor is the cultural tension that can emerge between traditional scientific research teams and AI professionals.
Machine learning development is inherently iterative. It involves rapid experimentation, statistical uncertainty, and continuous model refinement. Pharmaceutical research, by contrast, has historically prioritised biological validation, controlled experimental design, and the accumulation of incremental evidence. These are not incompatible approaches, but they do require active management to align.
When AI teams are positioned as analytical support functions, providing outputs for researchers to consume rather than shaping the direction of inquiry, candidates correctly perceive that their work will have limited influence. The organisations that avoid this dynamic are those that embed AI specialists directly within research programmes, with clear co-ownership of scientific outcomes.
Perhaps the most significant shift in the competitive landscape over recent years is the emergence of AI-first drug discovery companies. Organisations such as Recursion Pharmaceuticals, Exscientia, and Insilico Medicine have built their entire research platforms around machine learning from the outset.
For AI professionals, these companies offer a distinctive combination: engineering-driven cultures, modern technology stacks, rapid experimentation cycles, and direct collaboration between AI researchers and scientists working on the same problems.
Large pharmaceutical companies now compete not only with technology firms but also with scientifically credible organisations where AI is not a transformation initiative; it is the core operating model. This materially changes the employer value proposition that pharma needs to articulate.
Working across European life sciences companies, several patterns appear with sufficient consistency to be worth noting explicitly.
Compared with traditional scientific or commercial roles, AI and machine learning positions typically require extended timelines. Candidate pools narrow significantly once both technical depth and life sciences exposure are required. Technical evaluation adds process complexity. And alignment between scientific and engineering hiring stakeholders, who may assess candidates through different lenses, can introduce delays that compound over time.
Organisations that treat AI hiring as equivalent in complexity to a standard R&D appointment consistently underestimate the resource required.
Strong AI candidates approach employers analytically. They assess data environments, infrastructure maturity, the credibility of technical leadership, and the clarity of AI’s role within the broader research strategy. Companies that provide transparent, specific answers to these questions during the hiring process, rather than deferring to general ambition statements, see meaningfully higher offer acceptance rates.
The search for a single candidate capable of covering machine learning, software engineering, and biological modelling simultaneously is understandable but rarely productive. In practice, the highest-performing AI teams we observe are built around complementary expertise: machine learning engineers paired with computational biologists, data engineers supporting domain experts in chemistry or clinical science. Designing for team capability, rather than individual comprehensiveness, produces faster hiring and better outcomes.
Pharmaceutical companies that consistently attract strong AI talent tend to share a number of common approaches.
Rather than hiring for generic AI capability, they identify the precise scientific challenge they want to address - whether that is improving target identification, accelerating molecular screening, or predicting clinical outcomes. Clearly scoped problems attract candidates motivated by meaningful work, not just by technical complexity.
Effective AI capability in pharma is a team property. Building cross-functional groups that combine machine learning engineers, data scientists, computational biologists, and domain experts produces more durable results than searching for rare hybrid profiles.
Accessible, well-structured data is not just an operational requirement - it is a material factor in whether strong candidates choose to join and stay. Organisations that invest in modern data platforms are significantly more competitive in the talent market.
AI talent markets move quickly. Extended interview processes, even when justified internally, result in candidate drop-off. Reducing stages, accelerating decisions, and maintaining candidate engagement throughout the process directly impact offer acceptance rates.
The challenge of hiring AI talent in pharma is, at its core, an organisational readiness issue as much as a recruitment one. Talent strategy and data strategy are not separate workstreams; they are interdependent. How well an organisation has structured its data, defined its AI mandate, and positioned its teams to work together will largely determine its competitiveness in the market for the people it needs.
The World Economic Forum identifies AI and machine learning specialists as among the fastest-growing and hardest-to-fill roles globally. That pressure will not ease.
Organisations that address the structural foundations of a clear AI strategy, accessible data, interdisciplinary team design, and efficient hiring processes will find that attracting strong AI professionals becomes substantially more achievable. Those who continue to treat it as a pure recruitment challenge, divorced from these broader conditions, are likely to find the same problems persisting regardless of how actively they recruit.
Hiring AI and data specialists in life sciences requires more than access to candidates. It requires understanding how technical expertise, scientific knowledge, and organisational readiness intersect.
At Panda International, we work with pharmaceutical, biotech, and medtech companies across Europe to identify and secure specialists operating at the intersection of AI, data science, and life sciences.
Whether you are:
building a new AI capability
scaling an existing data science team
or looking to strengthen interdisciplinary AI research groups
our team can help you access talent with the right combination of technical depth and scientific context.
If you would like to discuss your AI or data hiring strategy, feel free to get in touch with our team.
